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Characterization of a novel type III CRISPR-Cas
effector provides new insights into the allosteric
activation and suppression of the Cas10 DNase
Jinzhong Lin 1, Mingxia Feng1,2, Heping Zhang3 and Qunxin She4
Abstract
Antiviral defense by type III CRISPR-Cas systems relies on two distinct activities of their effectors: the RNA-activated
DNA cleavage and synthesis of cyclic oligoadenylate. Both activities are featured as indiscriminate nucleic acid
cleavage and subjected to the spatiotemporal regulation. To yield further insights into the involved mechanisms, we
reconstituted LdCsm, a lactobacilli III-A system in Escherichia coli. Upon activation by target RNA, this immune system
mediates robust DNA degradation but lacks the synthesis of cyclic oligoadenylates. Mutagenesis of the Csm3 and
Cas10 conserved residues revealed that Csm3 and multiple structural domains in Cas10 function in the allosteric
regulation to yield an active enzyme. Target RNAs carrying various truncations in the 3ʹ anti-tag were designed and
tested for their influence on DNA binding and DNA cleavage of LdCsm. Three distinct states of ternary LdCsm
complexes were identified. In particular, binding of target RNAs carrying a single nucleotide in the 3ʹ anti-tag to LdCsm
yielded an active LdCsm DNase regardless whether the nucleotide shows a mismatch, as in the cognate target RNA
(CTR), or a match, as in the noncognate target RNA (NTR), to the 5′ tag of crRNA. In addition, further increasing the
number of 3ʹ anti-tag in CTR facilitated the substrate binding and enhanced the substrate degradation whereas doing
the same as in NTR gradually decreased the substrate binding and eventually shut off the DNA cleavage by the
enzyme. Together, these results provide the mechanistic insights into the allosteric activation and repression of LdCsm
enzymes.
Introduction
CRISPR-Cas (clustered regularly interspaced short
palindromic repeats (CRISPR)–CRISPR-associated (Cas))
systems constitute the adaptive and heritable immune
system in bacteria and archaea, which mediates antiviral
defense against invasive genetic elements in a small RNA-
guided fashion1–8. The immune system consists of two
parts: CRISPR arrays containing spacers derived from
invading nucleic acids, and cas gene cassettes coding for
enzymes or structural proteins that function in mediating
the CRISPR immunity. CRISPR-Cas systems are classified
into two broad classes based on the composition of their
effector complexes: those of Class 1 carry multi-subunit
effectors and those of Class 2 possesses a single effector
protein, and these antiviral systems are further divided
into six main types (types I–VI) with >20 subtypes9–11.
Type III CRISPR systems are unique because they exhibit
both RNA interference and DNA interference in vivo to
protect their microbial hosts against invading nucleic
acids4,12–23. Three activities are associated with these type
III immune systems, including target RNA cleavage18,24–30,
target RNA-activated indiscriminate single-stranded (ss)
DNA cleavage, a secondary DNase activity15,19,20,31–37, and
synthesis of cyclic oligoadenylate (cOA), a second messen-
ger that activates RNases of Csm6/Csx1 families, mediating
cell dormancy or cell death38–45. Activation of the immunity
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requires mismatches between the 3ʹ anti-tag of a cognate
target RNA (CTR) and the 5ʹ tag of crRNA, whereas the full
match between the 3ʹ anti-tag of noncognate target RNA
(NTR) and the 5ʹ tag of crRNA completely represses the
immune response (see reviews46–49). Upon activation by the
secondary messenger, Csx1/Csm6 RNases exhibit indis-
criminate cleavage of viral and cellular RNAs, leading to cell
dormancy or cell death to curb virus infection38–43,50,51. It is
further believed that the type III CRISPR DNase eventually
clears up remaining invading nucleic acids52, whereas the
cOA secondary messenger is to be removed by ring
nucleases53, allowing cells recover from the type III immune
response and restore the growth.
Structure of the Streptococcus thermophilus III-A
(StCsm) effector complex has recently been resolved.
This includes that of the StCsm binary complex and those
of the StCsmCTR and StCsmNTR ternary effector com-
plexes. The two ternary complexes have undergone major
conformational change, relative to the binary one, but the
active StCsmCTR complex and the inactive StCsmNTR
complex show minimal conformational change except for
the fact that the 3ʹ anti-tag of CTR and that of NTR are
placed in different channels54. Very similar results were
obtained from the structural analysis of the Thermococcus
onnurineus Csm effector complex55 and the StCsm
effector of different composition56. In particular, the
active site of these Csm DNases exhibits little difference
between the NTR-bound effector complex and the cor-
responding CTR-bound effector complex. As a result, the
process of the activation of a binary Csm complex by CTR
as well as its inhibition by NTR remains elusive.
To gain an further insight into the molecular mechanisms
of the allosteric regulation of type III-A effector complexes,
we characterized a Csm present in Lactobacillus delbrueckii
subsp. bulgaricus (LdCsm). The effector complex was
reconstituted by the expression in, and purified from,
Escherichia coli. Investigation of the interactions between
purified effector complexes and their target RNAs unravels
an active ternary LdCsm complexes with CTR or NTR
carrying a single nucleotide at their 3ʹ anti-tag regions, and
these results provide a novel insight for allosteric activation
and repression of the LdCsm DNase.
Results
L. delbrueckii subsp. bulgaricus encodes a novel III-A
CRISPR-Cas system defective in cOA synthesis
The L. delbrueckii subsp. bulgaricus strain carries a type
III-A CRISPR-Cas system (LdCsm) including a CRISPR
array of 16 spacers (Fig. 1a), in addition to a type II
CRISPR-Cas9 system in another chromosome location
(GenBank: CP016393.1). This LdCsm system was chosen
for characterization since phylogenetic analyses of a
selected set of Cas10 proteins revealed that its Cas10, the
L. delbrueckii subsp. bulgaricus Csm1, is distantly related
to the Cas10 proteins that have been studied thus far
(Supplementary Fig. S1).
We chose to reconstitute the LdCsm effector in E. coli
since recombinant protein purification procedure has not
been established for this lactobacillus yet. Three different
E. coli vectors, i.e., p15AIE, pUCE, and pET30a, were
employed to clone all components of the immune system,
including the complete set of III-A cas genes, a His-tag
version of csm2, and a synthetic CRISPR array (Supple-
mentary Fig. S2). Expression of these plasmid-borne genes
in the same cell yielded all the III-A Cas proteins, a His-
tagged LdCsm2 protein, and crRNAs (Fig. 1b), which were
allowed to assemble into recombinant LdCsm ribonu-
cleoprotein complexes in E. coli. The resulting effector
complexes were then purified in two-step purification, the
nickel-His tag affinity chromatography and the size
exclusion chromatography (SEC). A single protein peak
appeared in 10–12ml in the SEC purification (Fig. 1c),
indicative of copurification of large complexes. Analysis of
these SEC samples by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) showed
that each SEC sample contained five protein bands cor-
responding to the predicted sizes of Csm1, Csm2, Csm3,
Csm4, and Csm5, respectively (Fig. 1d). The RNA com-
ponent was extracted from the effector complexes using
the Trizol agent. Denaturing PAGE analysis of extracted
RNAs by radio-labeling and northern blot analysis of
these RNAs by the radio-labeled DNA probe revealed 3
major RNA components of ~76, 38, and 32 nucleotides
(nts). The largest species represented the complete unit of
S1 crRNA carrying the 5ʹ-repeat handle+S1 spacer+3ʹ-
repeat handle, representing the Cas6-cleaved crRNA
product of a single spacer, whereas the two smaller RNA
species were matured crRNAs (Fig. 1e and Supplementary
Fig. S3). Together, these results indicated that LdCsm
ribonucleoprotein complexes were reconstituted in E. coli.
Since F5–F7 fractions mainly contained the LdCsm
complex of 32 nt crRNA (Fig. 1e), the smallest ribonu-
cleoprotein effector complex, they were pooled together,
annotated as LdCsm, and characterized.
To test whether the E. coli-expressed effector could be
active in RNA cleavage, LdCsm was mixed with four dif-
ferent radio-labeled RNAs individually, i.e., (a) a non-
homologous RNA, S10, (b) the protospacer target RNA
(PTR), S1–40, lacking any 3ʹ anti-tag, (c) the CTR, S1–46,
exhibiting mismatches between its 6 nt 3ʹ anti-tag and the 5ʹ
tag of the corresponding crRNA, and (d) the NTR, S1–48,
possessing the fully complementary sequence between its 3ʹ
anti-tag and the 8 nt 5ʹ tag of the crRNA (Fig. 2a). These
reaction mixtures were incubated at 37 °C for 10min and
analyzed by denaturing PAGE. We found that, while the
non-homologous RNA was not a substrate of LdCsm
(Supplementary Fig. S4a), the effector cleaved all three
homologous target RNAs in 6-nt periodicity with similar
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efficiencies. These results indicated that LdCsm possesses
the backbone RNA cleavage activity and 3ʹ anti-tag
sequences on target RNAs do not influence the RNA
cleavage (Fig. 2b). Then all three target RNAs were tested
for their capability of mediating RNA-activated DNA
degradation to S10–60, a single-stranded non-homologous
DNA substrate (Supplementary Table S1). As shown in
Fig. 2c, only CTR activated the LdCsm DNase, indicating
that mismatches between the 3ʹ anti-tag of the target RNA
and the corresponding 5ʹ tag of crRNA are essential for the
activation. These results are in good agreement with those
reported for other characterized type III CRISPR-Cas sys-
tems15,17,19,20,31,34,35. We further tested the minimal con-
centration of CTR is required for the ssDNase activity of
LdCsm. To do that, a fluorophore quencher-labeled 16-nt
poly-dT ssDNA reporter (FAM-poly-16T-BHQ1) contain-
ing a 5ʹ-FAM (5ʹ-carboxyfluorescein) and 3ʹ-BHQ1 (3ʹ-
Black Hole Quencher-1) was synthesized and employed as
ssDNA substrate. Reactions containing 50 nM LdCsm and a
wide range of concentrations of CTR (0–10 nM) were set
up using a microplate. the result showed that 0.5–1 nM
CTR is efficient to activate the ssDNase activity of LdCsm
(Supplementary Fig. S5).
To date, all studied type III effectors are capable of
producing cOAs, a secondary messenger that activates
CRISPR-associated Rossmann fold domain RNases of the
Csm6/Csx1 family for general degradation of cellular
RNAs38–42. To investigate whether LdCsm could also do
that, the effector was mixed with ATP and CTR in the
presence of Mg++ and incubated for 2 h. Samples were
analyzed by denaturing PAGE. As shown in Fig. 2d,
whereas Sulfolobus islandicus III-B Cmr-α (a positive
reference38) consumed almost all 100 μM ATP for cOA
synthesis, LdCsm did not produce any detectable cOA in
the same reaction set-up. We repeated the experiments
several times and also tested with a number of different
metal ions but constantly failed to detect any cOA in the
ATP reaction (Supplementary Fig. S4f).
We noticed that LdCsm1 carries a QGDD motif in Palm
2, the active site for cOA synthesis, which differs from the
GGDD consensus (Supplementary Fig. S6a). To test
whether the occurrence of glutamine (Q597) residue in
the motif could be responsible for cyclase inactivation in
LdCsm, a Q597G substitution mutant was constructed to
restore the common GGDD motif in LdCsm1, denoted
Csm1Q597G. Characterization of the resultant mutated
Fig. 1 Cloning, expression, and purification of the L. delbrueckii subsp. bulgaricus Csm complex in E. coli. a Schematic of the LdCsm system.
LdCsm genes and the adjacent CRISPR assay are indicated with filled large arrows and small rectangles, respectively. Line with an arrowhead denotes
the promoter of the csm gene cassette and the direction of transcription. b Strategy for reconstitution of the LdCsm effector in E. coli. LdCsm genes
(cas6+ csm1–5 genes) were cloned into p15AIE, yielding p15AIE-cas (Supplementary Fig. S2). A CRISPR array carrying 10 copies of S1 spacer was
generated and inserted into pUCE, giving pUCE-S1 (Supplementary Fig. S2). LdCsm2 was cloned into pET30a, giving pET30a-Csm2 that yields the His-
tagged Csm2 upon plasmid-born gene expression in the cell. All three plasmids were introduced into E. coli BL21(DE3) by electroporation. c UV
spectrum of SEC purification of LdCsm effector complex. E. coli cell extracts were employed for Nickel-His tag affinity purification of LdCsm2 by which
LdCsm effector complexes were copurified. The resulting protein samples were further purified by SEC. Blue: UV absorbance at 280 nm; red: UV
absorbance at 254 nm. d SDS-PAGE analysis of SEC samples collected in the peak region. M: protein mass marker; Input: proteins purified by nickel
Csm2-His affinity chromatography. e Denaturing gel electrophoresis of 5ʹ-labeled RNAs from LdCsm samples. RNAs were extracted from the SEC-
purified LdCsm samples. M: RNA size ladder.
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effector revealed that the GGDD-restored LdCsm still
appeared to be inactive in cOA synthesis (Supplementary
Fig. S4f). To this end, the LdCsm cyclase inactivation
must not have resulted from any spontaneous mutation at
the Cas10 cyclase active site.
LdCsm system mediates anti-plasmid interference in E. coli
To investigate whether the LdCsm system could med-
iate DNA interference in vivo, three test plasmids were
constructed using pBad, an E. coli vector exhibiting
arabinose-inducible expression. These included pBad-
eGFP (pBad-G), a reference plasmid, and two
protospacer-carrying plasmids: one containing the CTR-
S1 protospacer-GFP fusion gene (pBad-CTR), and the
other possessing the NTR-S1 protospacer-eGFP (pBad-
NTR) (Fig. 3a). Meanwhile, E. coli strain for the in vivo
assay was generated by introduction of the expression
plasmid p15AIE-Cas-S1 into E. coli BL21(DE3) by elec-
troporation. The rationale of the experiment is that
plasmid-borne gene expression from p15AIE-Cas-S1
would yield binary LdCsm effector complexes in the
host cells, which would mediate anti-plasmid activity if a
CTR was to be expressed from a test plasmid. In addition,
since the expression of CTR-S1 or NTR-S1 target RNA is
controlled by the Bad promoter that confers very strin-
gent arabinose-inducible expression, target RNAs would
only be synthesized in L-arabinose media but not in
glucose media. Therefore, examination of colony-
formation efficiency of each plasmid on both arabinose
plates and glucose media would reveal in vivo
transcription-dependent anti-plasmid interference of the
immune systems to be tested (Fig. 3b).
All test plasmids were introduced into the genetic host
by transformation, and transformed E. coli cells were
Fig. 2 Biochemical characterization of the LdCsm effector complex. a Schematic of three different homologous target RNAs: CTR cognate target
RNA carrying 6-nt 3ʹ anti-tag with mismatch to the 5ʹ tag of the corresponding crRNA, NTR noncognate target RNA containing 8-nt 3ʹ anti-tag that is
complementary to the 5ʹ tag of the corresponding crRNA, PTR 40 nt protospacer target RNA completely lacking 3ʹ anti-tag. b Analysis of target RNA
cleavage by LdCsm. Different target RNAs (50 nM) were individually mixed with 50 nM LdCsm and incubated for 10 min. The resulting samples were
analyzed by denaturing PAGE. Duplex: Duplex of crRNA and substrate. c Analysis of RNA-activated ssDNA cleavage by LdCsm. 50 nM S10–60 ssDNA
substrate was mixed with 50 nM LdCsm and 500 nM of each of the target RNA and incubated for 10 min. Samples were analyzed by denaturing
PAGE. d Analysis of cOA synthesis by LdCsm. Approximately 2 nM [α-32P]-ATP was mixed with a range of cold ATP (48 nM–1 mM) and incubated with
50 nM LdCsm in the presence of 500 nM CTR for 120 min; the S. islandicus Cmr-α complex was used as the positive reference.
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plated on 6 different medium plates containing 0.5%
glucose or arabinose of different contents (0.01–0.08%).
Following transformation data were obtained: (a) pBad-G
and pBad-NTR produced very similar numbers of trans-
formants on all 6 growth media, (b) pBad-CTR gave very
similar transformation efficiency data on plates containing
glucose or very low concentrations of L-arabinose (0.01%
or 0.02%), (c) increasing the L-arabinose content in the
medium to 0.04% and 0.06% yielded ca. 10- and 100-fold
decrease in transformation efficiency, and (d) the presence
of 0.08% inducer completely abolished colony formation
by pBad-CTR-containing cells (Fig. 3c). These results
indicated, while NTR can effectively turn off the LdCsm
immunity, CTR is capable of conferring plasmid clearance
to the LdCsm system albeit it only possesses the RNA-
activated ssDNA cleavage activity. This is in contrast to
the current knowledge of antiviral mechanisms by type III
CRISPR-Cas systems in which the cOA signaling pathway
plays a main role in the immunity13,51,52,57,58, suggesting
that LdCsm represents the novel type III CRISPR-Cas
system, which exhibits the robust RNA-activated DNase
activity to resist the invasive plasmid.
Multiple Cas10 domains contribute to the LdCsm DNase
activity
The largest subunit Cas10 in type III-A effector com-
plexes contains four conserved domains, including a HD
domain, two Palm domains (Palm1 and Palm2), a Linker,
and a D4 structural region (Fig. 4a). Biochemical and
structural analyses of different type III CRISPR-Cas sys-
tems have revealed that the HD domain is responsible for
ssDNA cleavage15,19,20,31,34,35, and Palm1 and Palm2
domains function in cOA synthesis38–41,43, whereas the
Linker domain plays a regulatory role in both target
RNA-activated DNA cleavage and cOA synthesis54.
However, it remains unclear whether a concerted action
of different Cas10 domains would be required to yield
Csm DNase with optimal activity. The robustness of the
LdCsm DNase rendered it a good system for this
characterization.
Nine conserved amino acids present in the HD, Linker,
and Palm2 domains of LdCsm1 were chosen for sub-
stitution mutagenesis, giving six single domain mutants.
These included Csm1dHD, a HD domain mutant carrying
H15A and D16A double substitution, 3 Linker domain
mutants, i.e., Csm1LinE (E415A substitution), Csm1LinEC
(E415A and C416A substitutions), and Csm1LinCC
(C416A and C419A mutations), and 2 Palm2 domain
mutants, Csm1P2DxD (D541A and D543A substitutions)
and Csm1P2DD (D599A and D600A mutations). Then
some mutated motifs were combined, yielding double
domain mutations, including two HD/Linker mutants
(Csm1dHD_LinEC and Csm1dHD_LinCC), two HD/Palm2
mutants (Csm1dHD_P2DxD and Csm1dHD_P2DD) and
Fig. 3 Anti-plasmid activity of the LdCsm system. a Schematic of the test plasmids pBad-G, pBad-CTR, and pBad-NTR. Gene expression from these
plasmids is under the control of a L-arabinose-inducible Bad promoter. Therefore, mRNAs carrying CTR or NTR are expressed from the corresponding
plasmids (pBad-CTR or pBad-NTR) in the presence of L-arabinose, but their expression is completely repressed in glucose media. b Schematic of the
interference plasmid assay for determination of the LdCsm anti-plasmid activity. c Transformation efficiency data of the three different plasmids
obtained from different growth media.
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Fig. 4 (See legend on next page.)
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Csm1LinE_P2DxD, a Linker, and a Palm2 mutant (Supple-
mentary Table S2).
Each mutated csm1 gene was used to replace the wild-
type (WT) csm1 on p15AIE-cas, and the resulting plasmids
were introduced into E. coli to express LdCsm effectors
carrying each of the mutated LdCsm1 protein. These
mutated LdCsm effector complexes were obtained as
described for the WT LdCsm effector. The protein com-
ponents of these effector complexes were checked by SDS-
PAGE, and this showed that they all contained five dif-
ferent Csm subunits as for the WT LdCsm complex
(Supplementary Fig. S6b), indicating that none of these
Csm1 mutations affected the effector assembly. These
effector complexes were then tested for target RNA clea-
vage using S1–46, the CTR, as the substrate, and they all
exhibited the backbone cleavage (Supplementary Fig. S6c).
Next, RNA-activated DNase activity was examined for
each mutated complex in reactions containing 50 nM
effector, 50 nM ssDNA, and 500 nM CTR. For single
domain mutants, we found that all mutations (except for
Csm1P2DD) strongly impaired the ssDNase activity,
including Csm1dHD, Csm1LinE, Csm1LinEC Csm1LinCC, and
Csm1P2DxD (Fig. 4b). These results indicated that, in
additional to the HD domain, the putative cleavage site,
three other Csm1 motifs, i.e., E415 and C416 C419 in the
Linker region and DxD in the Palm2 domain are also
important for the LdCsm DNase. Analysis of the double
motif mutants further showed that, while combined
mutations of Csm1dHD_LinEC, Csm1dHD_LinCC and
Csm1dHD_P2DD possessed similar DNase activities relative
to those of single motif mutants, those of Csm1dHD_P2DxD
and Csm1LinE_P2DxD completely abolished the LdCsm
DNase cleavage (Fig. 4b). To this end, we concluded that
three Cas10 motifs, including HD, E415, C416 and C419
(Zinc finger) in the Linker as well as D451and D453
(DxD) in Plam2, play critical roles in the LdCsm DNA
cleavage.
To yield a further insight into the LdCsm DNA cleavage,
all these Csm1-mutated effector complexes were tested for
substrate binding in which 25, 50, or 100 nM effector
complex was mixed with 500 nM CTR and 5 nM radio-
labeled S1–60 ssDNA. After incubation for 3min, the for-
mation of LdCsm-ssDNA complexes was checked by
nondenaturing PAGE. As shown in Supplementary Fig. S6e,
the substrate affinity of these effector complexes fell into
three different categories. First, WT and LdCsm_Csm1P2DD
showed a strong binding (100% and ~80%), which is con-
sistent with their unimpaired DNase activity; second,
LdCsm_Csm1dHD and LdCsm_Csm1P2DxD retained ~30%
of the binding capacity of the WT LdCsm effector, whereas
the last group included those with mutations in Linker, only
exhibiting 5–20% of substrate binding. Taken together,
these data indicated the HD motif, the Zinc finger, and the
DxD motif function in facilitating substrate binding of the
LdCsm effector complex.
LdCsm1 Linker domain and Palm2 DxD motif function in
the allosteric control of the LdCsm DNase
The establishment of ssDNA binding assay with LdCsm
prompted us to investigate how target RNAs could reg-
ulate the LdCsm DNase. For this purpose, 400 nM S10
RNA (non-homologous RNA) and 500 nM of PTR, NTR
or CTR was mixed with 100 nM LdCsm and 5 nM of
labeled S1–60 DNA individually. After incubation at 37 °C
for 3min, samples were analyzed by non-denaturing
PAGE. We found that, while the WT LdCsm effector
showed little DNA-binding activity in the presence of non-
homologous RNA or NTR, PTR greatly enhanced the
DNA binding and that activity was further facilitated by
CTR for ca. fourfold (Fig. 4c, d), indicating that CTR
induces allosteric regulation on substrate binding of
LdCsm. These results also indicated that the activity of
LdCsm DNase involves the protospacer binding-induced
allosteric regulation, in which protospacer region-bound
facilitates the ssDNA substrate binding but the complexes
remain inactive, and CTR-dependent activation of the
LdCsm DNase. Therefore, 3ʹ anti-tag of both CTR and
NTR regulate LdCsm DNA binding.
(see figure on previous page)
Fig. 4 Effect of LdCsm1 mutations on ssDNA binding and cleavage by the LdCsm effector complex. a Domain architecture of the LdCsm1
protein. HD represents the HD-type nuclease domain; Palm 1 and Palm 2 denote the two cyclase domains; Linker is a domain that adjoins the Palm1
and Palm2 domains, consisting of four cysteine residues; D4 is located in the C-terminus rich in α-helices. Amino acid residues selected for alanine
substitution mutagenesis are indicated with their names and positions. b RNA-activated ssDNA cleavage by effectors carrying one of the constructed
LdCsm1 mutants. Fifty nM S10–60 ssDNA substrates were mixed with 50 nM mutated LdCsm carrying each of LdCsm1 mutant proteins and 500 nM
CTR and incubated for 10 min. Samples were analyzed by denaturing PAGE. c ssDNA binding by effectors carrying each of the constructed LdCsm1
mutants. Five nM labeled S10–60 ssDNA were incubated for 3 min with 100 nM of LdCsm effectors in the presence of 400 nM of non-homologous
RNA (S10 RNA) or 500 nM of one of the target RNAs, PTR or CTR or NTR. Samples were analyzed by non-denaturing PAGE. Red arrowheads indicate
the Csm–ssDNA complex. d Relative ssDNA binding between the wild-type LdCsm effector and its LdCsm1 mutated derivatives. The relative ssDNA-
binding activities were estimated by image quantification of the non-denaturing PAGE in c by the accessory analysis tool in Typhoon FLA 7000, the
ssDNA activity of LdCsm in non-homologous RNA was used as the standard and set up as 1. Results shown are average of three independent assays;
bars represent the mean standard deviation (±SD).
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Analyses of all above Csm1-mutated effector complexes
revealed that, while five mutated effectors
(LdCsm_Csm1P2DD, LdCsm_Csm1dHD, LdCsm_Csm1LinCC,
LdCsm_Csm1dHD_LinCC, and LdCsm_Csm1dHD_P2DD)
exhibited a pattern of target RNA activation that is very
similar to that of the WT LdCsm, those carrying E415A
and/or alanine substitutions in Palm2 DxD did not show
such a significant CTR-enhanced ssDNA substrate binding;
their CTR and PTR ternary complexes basically remained
inactive (Fig. 4c, d). These results indicated that, among the
three motifs essential for the LdCsm DNase, HD is not
involved in CTR-induced allosteric regulation of LdCsm,
whereas both E415 and P2-DxD are essential for the
allosteric regulation.
Taken together, our results unraveled two distinctive
functions for the Cas10 protein: (a) consistent with the
results obtained with other type III effectors, the HD
motif of LdCsm1 hosts the catalytic site of the DNase; (b)
E415 and P2-DxD are involved in mediating allosteric
regulation of the ternary effector to yield active enzyme.
Identification of Csm3 amino acids involved in the
regulation of the LdCsm DNase
The ssDNA substrate-binding assay revealed that the
PTR-bound ternary LdCsm showed a higher substrate
binding activity compared with LdCsm with non-
homologous RNA (Fig. 4c), indicating that the proto-
spacer region-bound drives certain regulation of LdCsm
complex. To yield a further insight into the mechanism,
Csm3 and subjected to substitution mutation to yield
Csm3 variants, with which mutated effector complexes
were purified and characterized in vitro.
Alignment of a selected set of Csm3 proteins revealed a
number of conserved amino acids among which many
have a structural function or form the intermolecular
contacts with crRNA or target RNA (Supplementary Fig.
S7). There are three conserved residues: H20, D34, and
D106 that do not play a structural role or crRNA or target
RNA binding (LdCsm3 number). D34 was the predicted
active site of the LdCsm RNase, whereas functions of the
remaining two amino acids were elusive. To study that, we
constructed several LdCsm3 mutants, including alanine
substitution of H20, D34, or D106 as well as double
substitutions (H20/D34 and D34/D106). LdCsm effector
complexes carrying each of these Csm3 mutations
(designated Csm3H20A, Csm3D34A, Csm3D106A, Csm3H20/
D34-A, and Csm3D34/D106-A) were purified from E. coli and
characterized. Target RNA cleavage assay showed that,
while neither Csm3H20A nor Csm3D106A substitutions
influenced the target RNA cleavage, Csm3D34A substitu-
tion greatly impaired the RNA cleavage of the effector
(Fig. 5a). These results confirmed that D34 is the active
site of target RNA cleavage of the LdCsm system as
demonstrated for the conserved aspartic acid residue in all
other known type III CRISPR-Cas systems. Analysis of
RNA-activated ssDNA cleavage showed that the LdCsm
complex containing the Csm3D34A substitution exhibited
higher ssDNase activity relative to WT complex, and
DNase activity was strongly impaired in the remaining
four mutated Csm3 complexes (Fig. 5b).
To investigate their possible roles in spatiotemporal
regulation, these Csm3 mutated complexes were incu-
bated with the ssDNA substrate in the presence of dif-
ferent RNAs and analyzed for their substrate binding
activity. We found that, while Csm3H20A substitution
impaired ssDNA binding for all tested RNAs, Csm3D34A
exhibited a higher ssDNA substrate-binding enhancement
in the presence of PTR vs. non-homologous RNA than
WT complex in the presence of either RNA (ca. threefold
vs. twofold, respectively), which could be due to the
impaired target RNA cleavage that allows a longer per-
sistence of the ternary complex. However, Csm3D106A
substitution and the double substitutions Csm3H20/D34-A
and Csm3D34/D106-A did not show such a significant PTR-
induced ssDNA substrate-binding enhancement relative
to WT complex (Fig. 5c, d). Together, these results con-
firmed that CTR-activated LdCsm ssDNase activity
involves the protospacer binding-induced allosteric reg-
ulation, consistent with the results obtained from struc-
tural analysis with other Csm or Cmr complexes54,55,59.
These results also indicated that two Csm3 residues, H20
and D106, are involved in mediating regulation of the
ternary LdCsm complex to yield active enzyme.
Identification of different target RNA-LdCsm ternary
complexes with distinctive substrate binding and DNA
cleavage
To investigate how target RNA could activate the LdCsm
DNase, 3′-truncation variants of the CTR were generated,
carrying +1, +2, +3, +4, +5, and +6 nt of the 3ʹ anti-tag
region of CTR (annotated as CTR+1 to CTR+6) as well as
the full-length CTR (CTRFull) (Supplementary Table S1).
Each target RNA was tested for its capability to facilitate
DNA binding and DNA cleavage by LdCsm. As shown in
Fig. 6a, while the binary LdCsm showed little DNA binding,
PTR, the target RNA lacking any 3ʹ anti-tag sequence,
greatly facilitated the substrate binding of the LdCsm
complex (ca. 55% of CTR-LdCsm) but it failed to mediate
DNA cleavage. Next, when CTR1, a target RNA that
extended the PTR by a nucleotide at the 3ʹ anti-tag posi-
tion, was used to form a ternary effector complex with
LdCsm, the resulting effector not only showed further
increased substrate-binding activity (ca. 90% of the full
activity) but also activated the DNA cleavage (ca. 35% of
full activity). This suggested that a single nucleotide at the
3ʹ anti-tag of CTR is efficient to convert the inactive ternary
LdCsm complex to an active one. Finally, DNA cleavage
activity by the LdCsm effector peaked with CTR+4 that
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Fig. 5 Effect of LdCsm3 mutations on the ssDNA cleavage and binding of LdCsm. a Target RNA cleavage of LdCsm3 mutated derivatives. Fifty
nM of S1–46 RNA were incubated with 50 nM of LdCsm or the indicated mutant derivatives for 10 min, and the samples were analyzed by denaturing
PAGE. Duplex: Duplex of crRNA and substrate. b RNA-activated ssDNA cleavage by effectors carrying one of the constructed LdCsm3 mutants.
Reaction conditions were the same as in Fig. 4b. c ssDNA binding by effectors carrying each of the constructed LdCsm3 mutants. Reaction conditions
were the same as in Fig. 4c. d Relative ssDNA binding between the wild-type LdCsm effector and its LdCsm3 mutated derivatives. The ssDNA activity
of LdCsm in non-homologous RNA was used as the standard and set up as 1. Results shown are average of three independent assays; bars represent
the mean standard deviation (±SD). The red arrow indicates the ssDNA-LdCsm complex.
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Fig. 6 Target RNA-directed allosteric regulation of LdCsm involves activation and deactivation mechanisms. a CTR activates the LdCsm
DNase. b NTR mediates autoimmunity avoidance by deactivation. Reactions were set up with 5 nM S10–60 ssDNA, 100 nM of LdCsm, and 400 nM
non-homologous RNA (non-h. RNA) or 500 nM target RNA. After addition of one of the target RNAs, the mixture was incubated at 37 °C for 3 min.
Samples were then analyzed by non-denaturing PAGE (in this page) or denaturing PAGE (Supplementary Fig. S8). Red arrowheads indicate the
LdCsm–ssDNA complex. Relative ssDNA binding and percentage ssDNA cleaved of LdCsm facilitated by each of these target RNAs were estimated by
image quantification of bands on non-denaturing PAGE and denaturing PAGE, using the accessory analysis tool equipped with a Typhoon FLA 7000.
For the quantification of the substrate binding, the amount of ssDNA-LdCsm-CTR+6 complex is arbitrarily defined as 1. Results of average of three
independent assays are shown with bars representing the standard deviation (±SD).
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carries 4 nt 3ʹ anti-tag of CTR, which could have completed
the allosteric regulation of the immune system (Fig. 6a).
NTR inhibits the LdCsm DNase by preventing substrate
binding
The same approach was then employed to investigate
how NTR could inhibit the LdCsm DNase. Truncated
derivatives of NTR were generated (i.e., NTR+1–NTR+6)
for the CTR derivatives, and in addition, a few PTR
truncations (PTR−8 to PTR−2) were also made (Supple-
mentary Table S1). These target RNAs were tested for
their capability of facilitating substrate binding and clea-
vage as described above. We found that PTR and its
truncated derivatives (PTR−4–PTR−8) showed marginal
differences both in ssDNA binding and in ssDNA cleavage,
suggesting that these ternary complexes could belong to
the same category, equivalent to the stage of the binary
LdCsm effector (Fig. 6b). While PTR−2 and PTR showed
similar effects on ssDNA binding, NTR+1, however,
mediated a major stimulation to the LdCsm DNA binding
(ca. 70% of the full activity), and it also facilitated the DNA
cleavage (ca. 35% of full activity), and in fact, the stimu-
lating effect by NTR+1 is comparable to that of CTR+1
(Fig. 6). These results not only implied that the first
nucleotide at the 3ʹ anti-tag of NTR can still allow acti-
vation of the HD nuclease domain but also indicated that
the process of repression by NTR shares some common
activation with the CTR-dependent activation process of
LdCsm DNase. Thereafter, extension of the 3ʹ anti-tag of
NTR greatly reduces the DNA binding and gradually
decreases DNA cleavage (Fig. 6b), suggesting that the
interaction between 3ʹ anti-tag of NTR and the 5ʹ tag of
crRNA could have deactivated the enzyme by restricting
the accessibility of the ssDNA substrate to the active site.
Discussion
Type III CRISPR-Cas systems characterized thus far
show three different interference activities: target RNA
cleavage, RNA-activated indiscriminate DNA cleavage,
and cOA synthesis among which the latter two activities
are responsible for the DNA interference by these systems,
whereas target RNA cleavage plays a regulatory role (see
reviews46,47,49). Here we report a type III-A subtype
CRISPR-Cas system that shows robust RNA-activated
ssDNA cleavage but lacking cOA synthesis. This is con-
sistent with the fact that the genome of the L. delbrueckii
subsp. bulgaricus genome does not code for any detectable
Csm6 homologs. Interestingly, we find that a plasmid-
borne LdCsm system is sufficient to mediate interference
plasmid clearance in E. coli. This suggests that the LdCsm
system probably only utilizes the RNA-activated ssDNase
to mediate the antiviral immunity in the original host. We
have also explored the simplicity of the LdCsm antiviral
mechanism for investigating mechanisms of the DNA
cleavage by type III CRISPR-Cas systems, and our research
has yielded mechanistic insights into the target RNA-
mediated activation and repression of the LdCsm DNase.
Structures of several type III effector complexes have
been solved54–56,59,60, and these analyses have revealed
that formation of target RNA-Csm ternary effectors
involves a minimal conformational change that is very
similar between the CTR ternary effectors and the cor-
responding NTR ternary ones, although only the former
has been activated for DNA cleavage54–56. As a result,
there is no major structural difference at the catalytic site
of active vs. inactive Csm DNases, and the only difference
is the 3ʹ anti-tag sequences of the two different types of
target RNAs that are individually placed in different
channels in their structures54. Furthermore, in the struc-
ture of the PTR-StCsm complex, major conformational
change also occurs although the target RNA lack any 3ʹ
anti-tag. Since structure of a DNA substrate-bound Csm
effector complex has not been resolved, how these effec-
tors interact with their DNA substrates remains to
unknown. For this reason, the only biochemical criterion
to distinguish different effector complexes is to analyze
their DNA cleavage activity. In this work, we have
established a ssDNA-binding assay for LdCsm, and our
detailed analysis of substrate binding for this immune
system has revealed that different target RNAs are capable
of facilitating differential substrate binding and DNA
cleavage to the LdCsm effector. Thus it is very interesting
to study how allosteric regulation differentially influences
the two activities of the LdCsm DNase.
Structural analysis of StCsm by You et al.54 has indi-
cated that the Cas10 Linker domain functions in med-
iating conformational change. Here we find that that both
the DxD motif in Palm 2 and the E415 residue in the
Linker domain play an essential role in mediating the
allosteric regulation of the LdCsm complex in vitro. To
date, detailed functions of the Cas10 linker E415 and P2
DxD motifs have not been studied for other type III
CRISPR-Cas systems, although all three amino acids are
well conserved in Cas10 proteins (Supplementary Fig.
S6a). Therefore, it is of a great interest to investigate
whether their functions revealed for LdCsm represent a
general mechanism for all type III immune systems.
In this paper, we have presented the detailed bio-
chemical analysis of substrate binding by the LdCsm
effector complex, and our analysis shows that the Cas10
Zinc finger modulates the enzyme substrate binding since
E415A substitution yielded an enzyme with greatly
reduced DNA binding and inactive in DNA cleavage (Fig.
4). As E415 is probably part of the Zinc finger motif, this
suggests that the Cas10 Zinc finger domain can have dual
function in this immune system, namely, both as an
executor to the allosteric regulation and as a regulator to
substrate binding46,61. The other substrate-binding study
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was conducted by single-molecule fluorescence micro-
scopy analysis of Staphylococcus epidermidis Csm by
Wang et al.62. They find that Cas10 subunit is locked in a
static configuration upon NTR binding in which the
DNA-binding pocket of the effector appears to be in a
closed form, inaccessible to substrate. However, upon
CTR binding, Cas10 exhibits a larger conformational
space in the active site62. Together with our biochemical
data, it is thus plausible to predict that there exists a
substrate-binding pocket in the DNase of type III effector
complexes although this structural domain remains to be
illustrated by their structural analysis.
The possibility of characterization of effector complexes
for both substrate binding and DNA cleavage allows us to
identify several target RNA-LdCsm effector complexes
that exhibit differential activities, and we propose that
some of these effector complexes probably represent
intermediates for structural analysis to study the mole-
cular mechanisms of the CTR activation or NTR repres-
sion of the LdCsm system (Fig. 7). These include: (a) The
Fig. 7 Model of allosteric activation and repression of the LdCsm DNase. The previous works have proposed the initial recognition of nascent
transcript at the 5ʹ end of target RNA for type III complex, since both of Csm5 subunit in Csm complex and Cmr1 subunit in Cmr complex are crucial for
target RNA binding36,37,68. These suggested that the binary LdCsm effector complex interacts with target transcript initially at the 5ʹ end of target RNA
and further via sequence complementarity between the protospacer and the corresponding crRNA, leading to the formation of a ternary effector
complex with a major conformational change. Addition of a single nucleotide at the 3ʹ-end of protospacer RNA results in an important allosteric
change in the LdCsm DNase, giving an active enzyme. CTR-bound LdCsm exhibits the full level of substrate binding and DNA cleavage, whereas NTR-
bound LdCsm closes the substrate-binding pocket, which deactivates the DNase. Finally, multiple Csm3 subunits cleave the target transcripts, and
release of target RNA cleavage products restores the binary conformation, completing the spatiotemporal regulation of LdCsm systems.
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LdCsm-PTR complex showing an elevated level of sub-
strate binding but inactive in catalysis; (b) the LdCsm-
CTR+1 and LdCsm-NTR+1 exhibiting most of substrate
binding and catalysis activities, representing another type
of intermediates. There are two apparent features with the
two effectors: they differ from LdCsm-PTR only by the
first nucleotide present in the 3ʹ anti-tag of target RNAs,
and the nucleotide in CTR is different from that in NTR.
Thus this nucleotide could functions as a trigger to induce
the major allostery in LdCsm ternary to yield an active
effector complex and the interaction between the effector
with the nucleotide should not be specific; (c) LdCsm-
CTR+4 represents another effector complex that should
have adopted the same conformation since it exhibits the
maximal substrate binding and catalysis; and (d) finally
LdCsm-NTRFull represents the inactive conformation of
the effector that completely deactivate the LdCsm com-
plex, ensuring autoimmunity avoidance of the LdCsm
system (Fig. 7). These LdCsm effector complexes provide
good model for structural analysis to reveal the molecular
mechanisms of activation and repression of Csm DNases.
Materials and methods
Bacterial strains and growth conditions
L. delbrueckii subsp. bulgaricus ND04 (GenBank:
CP016393.1) was grown in MRS broth (Oxoid, UK) at 37 °C
without shaking. E. coli JM109 and BL21(DE3) were pro-
pagated in Luria-Bertani (LB) medium at 37 °C with
200 rpm/min shaking. If applicable, antibiotics were added
as the following: ampicillin (100 μg/ml, Sigma), kanamycin
(25 μg/ml, Sigma), and chloramphenicol (10 μg/ml, Sigma).
Construction of different vectors and plasmids
To construct a p15A replicon-based expression vector,
the origin fragment was obtained from pTRKH263, and
ampicillin-resistance gene (Amp) was derived from
pUC19 (New England Biolabs), whereas gene expression
cassette were amplified from pET30a (Novagen) by PCR,
using three sets of primers (p15A-F and p15A-R, Amp-F
and Amp-R, as well as LacI-F and T7-R) listed in Sup-
plementary Table S1. Ligation of these DNA fragments
generated the expression vector p15AIE (Supplementary
Fig. S2a). The same strategy was employed to construct
pUCE in which the origin was amplified from pUC19, and
chloramphenicol resistance gene was obtained from
pCI372, whereas the expression cassette from pET30a,
using the primer sets of pUC, Cm, and T7, respectively
(Supplementary Table S1). Ligation of these DNA frag-
ments gave pUCE (Supplementary Fig. S2b).
The vector for invader plasmid assay was constructed in
two steps. First, fragment 1 containing the origin of pBR322
and kanamycin resistance gene (Kan) was obtained from
pET30a by PCR (pBR-Kan primers); second, DNA frag-
ments carrying an arabinose-inducible Bad promoter,
multiple cloning sites (MCS), and transcriptional termi-
nator (T) were generated by PCR from E. coli BL21(DE3)
genome and plasmid pELX164, using the primer sets of
PBad and MCS-T listed in Supplementary Table S1,
respectively, and they were then fused together by splicing
overlapping extension PCR (SOE-PCR)65; third, ligation of
the fragment 1 and the SOE DNA fragment yielded pBad
vector. Then three DNA fragments carrying eGFP gene
were amplified from pEGFP-N166 by PCR using GFR-F/
GFR-R, CTR-GFR-F/GFR-R, and NTR-GFR-F/GFR-R, and
insertion of each fragment into pBad individually gave
pBad-G, pBad-CTR, and pPBad-NTR. All primers
employed in this work are listed in Supplementary Table S1.
Chromosomal DNA was extracted from cells of L. del-
brueckii subsp. bulgaricus ND04 using the OMEGA
Genomic DNA Purification Kit (OMEGA Bio-tek). DNA
fragment covering the cas6-cas10-csm2-csm3-csm4-csm5
gene cassette was amplified by PCR with the primers SalI-
Cas6-F and NotI-Csm5-R using ND04 genome DNA as
template. The PCR product inserted into p15AIE via SalI
and NotI, yielding p15AIE-Cas. csm2 gene was amplified
from ND04 genome using primers Csm2-F and Csm2-R.
PCR product was then digested with NdeI and XhoI and
cloned into pET30a expression vectors, giving pET30a-
Csm2. To construct a CRISPR array plasmid, fusion PCR
amplification was performed using three primers Re-S1-F,
S1-R1, and Re-S1-R to generate the multiple copies of 36 nt
length repeats interspaced by multiple S1 spacer (40 nts) of
identical sequence, then PCR products of ~1 kb were
recovered from an agarose gel using an OMEGA Gel-
Purification Kit (OMEGA Bio-tek). The purified DNA
fragments were cloned into pJET1.2 (CloneJET PCR
Cloning Kit, Thermo Scientific). After confirming the
sequence of the synthetic CRISPR array on pJET clones
(GATC Biotech), the DNA fragment was amplified and
cloned into plasmid pUCE at the BglII site, yielding pUCE-
S1 carried 10 identical spacers (S1) in the CRISPR array.
Finally, plasmid p15AIE-Cas-S1 was constructed by inser-
tion of the CRISPR array into p15AIE-Cas at the NheI site.
Purification of LdCsm effector complexes from E. coli
Three plasmids (p15AIE-Cas, pUCE-S1, and pET30a-
Csm2) were introduced into E. coli BL21(DE3) by elec-
troporation, yielding a E. coli strain containing all three
plasmids. This bacterial strain was employed as host to
overexpress the LdCsm system. The strain was cultured in
200ml LB medium containing ampicillin, kanamycin, and
chloramphenicol (at 37 °C, 200 rpm) to the mid-log phase
(OD600 was 0.8), then IPTG was added to 0.3 mM and the
culture was further cultured at 25 °C for 16 h. Cells were
harvested by centrifugation at 5000 rpm for 5 min, and
cell pellets were resuspended in 20 ml buffer A [20 mM
Tris-HCl (pH 8.5), 0.25M NaCl, 20 mM imidazole and
10% glycerol], yielding cell suspension that was treated
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with a French press for cell lysis at 4 °C. Cell debris was
then removed from treated cell suspension by cen-
trifugation at 10,000 rpm for 30 min at 4 °C. The Csm
complex was captured on the HiTrap affinity column (GE
Healthcare) by LdCsm2 copurification and eluted with
buffer B [20 mM Tris-HCl (pH 8.5), 0.25M NaCl,
200mM imidazole, and 10% glycerol]. The resulting
LdCsm effector complex preparation was further purified
by SEC with Superdex 200 (GE Healthcare) using the
chromatography buffer [20 mM Tris-HCl (pH 8.5),
0.25M NaCl, and 5% glycerol]. SEC fraction samples were
analyzed by SDS-PAGE and those containing the com-
plete set and high quality of Csm complex components
were pooled together and used for further analysis. Csm
complex concentration was measured according to the
Bradford method using the protein assay kit (Thermo
Scientific) with bovine serum albumin as the standard.
Extraction and analysis of crRNA
The purified LdCsm complex (100 μl) was first mixed
with l00 μl Trizol agent (Sigma), and then 200 μl chloro-
form:isoamylalcohol (24:1, v/v) was added. After vortex for
30 s, the mixture was centrifuged at 12,000 rpm for 10min
at 4 °C. The upper phase was transferred into a new tube
and re-extracted with 200 μl chloroform:isoamylalcohol.
crRNA in the upper phase was precipitated with one
volume of isopropanol and washed twice with 1ml of 70%
ice-cold ethanol. The pellet was air-dried for 30min at the
room temperature and dissolved in 20 μl DEPC-H2O. Ten
nanograms of crRNA was 5ʹ-labeled with [γ-32P]-ATP
(PerkinElmer) using T4 polynucleotide kinase (New Eng-
land Biolabs) and separated on a 12% denaturing poly-
acrylamide gel. The labeled crRNAs were identified by
exposing the gel to a phosphor screen (GE Healthcare) and
scanned with a Typhoon FLA 7000 (GE Healthcare). For
northern blotting of crRNA, 100 ng of unlabeled crRNA
was mixed with equal volume of 2× RNA loading dye (New
England Biolabs) and fractionated in the 12% denaturing
polyacrylamide gel. Northern blotting analysis was con-
ducted as described previously67, using radio-labeled RNA
S1–40 (Supplementary Table S1).
Labeling of DNA and RNA substrates
All DNA, S10 (nonhomologous RNA), S1–40 (PTR),
S1–46 (CTR), and S1–48 (NTR) oligonucleotides were
purchased from IDT, other RNA oligonucleotides were
generated by in vitro transcription using the TranscriptAid
T7 High Yield Transcription Kit (Thermo Scientific; Sup-
plementary Table S1). DNA and RNA oligonucleotides to
be used as substrate for cleavage and binding assays were
purified by recovering the corresponding bands from either
a native polyacrylamide gel (for double-stranded DNA) or
from denaturing polyacrylamide gel (for ssDNA or RNA)
after electrophoresis. ssDNA and RNA substrates were 5ʹ
labeled with [γ-32P]-ATP and T4 polynucleotide kinase
followed by denaturing gel purification. Double-strand
DNA, bubble DNA, and R-loop DNA were generated as
described previously31.
Cleavage assay
Nucleic acid cleavage assays were conducted in 10 μl of
reaction containing the indicated amount of effector
complex and substrates in the cleavage buffer (50 mM
Tris-Cl (pH 6.8), 10 mM MgCl2, 50 mM KCl, 0.1 mg/ml
bovine serum albumin (BSA)]. In DNA cleavage assay,
500 nM (unless otherwise indicated) unlabeled RNA was
supplemented to activate DNA cleavage activity. Samples
were incubated at 37 °C and stopped for the indicated
time periods, and the reaction was stopped by addition of
2× RNA loading dye (New England Biolabs). For elec-
trophoresis, samples were heated for 3 min at 95 °C and
analyzed on an 18% polyacrylamide denaturing gel. RNA
ladders were generated by Decade™ Marker RNA
(Ambion) following the instructions and labeled by
[γ-32P]-ATP with T4 polynucleotide kinase. Results were
recorded by phosphor imaging.
Determination of cyclic oligoadenylate synthesis activity
Each reaction mixture contained 50 nM Csm complex,
500 nM unlabeled S1–46 RNA (CTR), ~2 nM [α-32P]-
ATP (PerkinElmer), and an indicated content of ATP in
50mM Tris-Cl (pH 6.8) and 0.1 mg/ml BSA supple-
mented with ions. Reactions were incubated at 37 °C for
120min, and 2× RNA loading dye was added at the
indicated time points to stop the reaction. Samples were
kept on ice until use. For electrophoresis, samples were
treated at 95 °C for 3 min and analyzed by 24% denaturing
PAGE. Gels were analyzed by phosphor imaging.
Electrophoretic mobility shift assay
ssDNA-binding assay was performed by incubating
different amounts of Csm complex (specified in each
experiment) with 5 nM 32P-5ʹ-labeled S10–60 ssDNA in
the cleavage buffer. All reactions were incubated at 37 °C
for the indicated time periods. Then the same volume of
2× native loading buffer [0.1% bromophenol blue, 15%
sucrose, w/v] was added, and the samples were immedi-
ately put on ice and kept there until needed for electro-
phoresis on an 8% nondenaturing polyacrylamide gel.
Electrophoresis was carried out at 4 °C using 40mM Tris
and 20mM acetic acid (pH 8.4 at 25 °C) as the running
buffer. Gels were analyzed by phosphor imaging.
Relative ssDNA-binding and cleavage activities of
LdCsm facilitated by each of these target RNAs were
estimated by image quantification of bands on non-
denaturing PAGE and denaturing PAGE, respectively,
using the accessory analysis tool equipped with a
Typhoon FLA 7000. Results of average of three
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independent assays are shown with bars representing the
mean standard deviation (±SD).
Mutagenesis of LdCsm1 and LdCsm3
LdCsm1 mutants were generated using the splicing
overlapping extension PCR protocol previously reported63.
In brief, several mutations were designed in the internal
partial overlapping primers, initial PCRs were preformed
using the external primer and their corresponding internal
primers to generate overlapping gene segments, and then
the two PCR products were fused together by overlapping
extension PCR. The resulting fragments were digested
with restriction endonuclease (DNA fragment containing
LdCsm1 H15D16A mutation was cleaved with SalI
and SacI, those carrying LdCsm1 E415A, E415C416A,
C416C419A, D541D543A, D599D600A, or Q597G were
digested with StuI and SacI). LdCsm3 H20A, D34A, and
D106A was obtained via StuI and KpnI. After purification,
these DNA fragments were inserted into the plasmid
p15AIE-Cas at the corresponding restriction sites, yielding
the plasmids carrying each designed LdCsm1mutation. All
mutations were verified by DNA sequencing (GATC
Biotech).
Plasmid interference assay
Plasmid interference assays were performed as pre-
viously described51. Briefly, an E. coli BL21(DE3) strain
carrying p15AIE-Cas-S1 (80 μl) was transformed with
100 ng of one of the following plasmids, pBad-G, pBad-
CTR, or pBad-NTR. Electroporation was performed in a
1-mm cuvette (Bio-Rad, USA), with the setting of 1600 V,
200Ω, and 25 μF, using a Gene Pulser II Electroporation
System (Bio-Rad). Then 920 μl of SOC medium was
immediately added to electroporated cells and incubated
with shaking (200 rpm) at 37 °C for 60min. A series of
dilutions were then made for each transformation, and
100 μl of each dilution was plated onto LB agar plates
containing 0.05 mM IPTG, Ampicillin, Kanamycin, and
various concentrations of L-arabinose. Plates were incu-
bated overnight at 37 °C, and the transformation efficiency
was calculated. Transformation experiments were con-
ducted for three independent times.
Fluorescence assay
The reaction mixture (20 μl in total) contains 50 nM
complex, the indicated concentration target RNA, in the
presence of 500 nM of FAM-poly-16T-BHQ1 ssDNA
substrate (Tsingke Biotechnology Company, Wuhan,
China). These reactions were incubated in a 384-well
black plate (Thermo fisher) and put on a fluorescence
plate reader (FLUOstar Omega) for up to 60min at 37 °C
with fluorescence measurements taken every 1 min (λex:
485 nm; λem: 535 nm). Background fluorescence values
were obtained by subtracting fluorescence values obtained
from reactions carried out in the absence of target RNA.
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